New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 1, 2014
17:05 EDTGPRO, AYI, TWTR, GEVA, RGEN, NFLX, SNYOn The Fly: Closing Wrap
Stocks on Wall Street were higher but the Dow will need to wait at least one more session before eclipsing 17,000 for the first time. The bluechip average, along with the S&P 500 and the Nasdaq, began the trading day in positive territory and remained there for the entire session. Following manufacturing reports from around the globe that were released today, investors will now be keying in on the week's big economic event, which is the U.S. monthly nonfarm payrolls report due Thursday. ECONOMIC EVENTS: In the U.S., Markit's manufacturing purchasing managers' index for June had a final reading of 57.3, which was a hair below the 57.5 flash estimate but up from May's 56.4 reading. ISM's manufacturing index slipped very slightly to 55.3 in June from May's 55.4 figure. Construction spending increased 0.1% in May, missing the forecast for 0.5% growth. In China, HSBC's PMI reading came in at 50.7, which was a bit below the flash reading but above the 50 mark that indicates expansion for the first time since December. In Europe, Markit's final eurozone manufacturing PMI for June came in at 51.8, which was down from 52.2 in the prior month and below the earlier flash estimate of 51.9, but still indicated expansion in the sector. COMPANY NEWS: Shares of Netflix (NFLX) climbed $32.50, or 7.38%, to $473.10 after Goldman Sachs upgraded the stock in a note to investors earlier today, predicting that Netflix's total worldwide market will more than double over the next three years and its subscriber growth will continue to exceed expectations... Twitter (TWTR) rose $1.08, or 2.64%, to $42.05 after hiring Anthony Noto as its new Chief Financial Officer. Noto served as a Managing Director in the Technology, Media and Telecom group at Goldman Sachs (GS), which had handled the social network's IPO, and prior to that had served as the CFO of the National Football League. MAJOR MOVERS: Among the notable gainers was GoPro (GPRO), which rose another $8.25, or 20.35%, to $48.80 in its fourth trading session since its IPO last Thursday. The action camera maker has advanced an incredible 66.78% since its IPO priced at $24.00 per share. Also higher was Regeneron (REGN), which advanced $20.92, or 7.41%, to $303.39 after Sanofi (SNY) disclosed in a regulatory filing that it plans to increase its beneficial ownership stake in its smaller pharmaceutical industry peer to 22.5% from 20.5%. Among the noteworthy losers was lighting solutions maker Acuity Brands (AYI), which fell $20.63, or 14.92%, to $117.62 after its sales and profits missed expectations. Also lower were shares of Synageva BioPharma (GEVA), which tumbled $14.35, or 13.69%, to $90.45 after the company reported that its sebelipase alfa drug had met its primary endpoint in a trial, but two research firms were lukewarm about the stock's outlook. INDEXES: The Dow was up 129.47, or 0.77%, to 16,956.07, the Nasdaq was up 50.47, or 1.14%, to 4,458.65, and the S&P 500 was up 13.09, or 0.67%, to 1,973.32.
News For NFLX;TWTR;GPRO;RGEN;AYI;SNY;GEVA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
March 17, 2015
05:50 EDTNFLXStocks with implied volatility movement; DD NFLX
Subscribe for More Information
05:40 EDTSNYSanofi upgraded to Outperform from Market Perform at Leerink
March 16, 2015
16:28 EDTNFLXOn The Fly: Closing Wrap
Subscribe for More Information
16:25 EDTTWTRTwitter initiated with a Buy at Brean Capital
Target $61.
16:00 EDTTWTROptions Update; March 16, 2015
Subscribe for More Information
13:56 EDTTWTRChances of Twitter launching fee-based service increasing, analyst says
Subscribe for More Information
10:50 EDTTWTRKing Digital seen benefiting from user base larger than Twitter, LinkedIn
Subscribe for More Information
10:44 EDTNFLXNetflix retreats after cut to sell on competition, cost concerns
The shares of Netflix (NFLX) are falling after research firm Evercore ISI downgraded the stock to Sell from Hold. Increased competition will force the company to increase its investments and the return from those investments is uncertain, the firm contends. WHAT'S NEW: In the U.S., technological advancements are enabling content providers to sell their programming to a wider range of Internet video distributors, Evercore ISI analyst Ken Sena wrote in a note to investors earlier today. Moreover, content providers themselves are now able to stream more of their programming online and obtain higher profits from doing so, Sena reported. The analyst noted that Apple (AAPL) recently obtained a three month exclusive deal to stream content form Time Warner's (TWX) HBO Now, while Yahoo (YHOO), Amazon (AMZN), and Hulu (DIS, CMCSA, NWSA) are all reportedly interested in obtaining streaming rights to "Seinfeld." Netflix's international expansion will not be sufficient to offset the increased competition, especially because foreign viewers are likely to watch less TV and be less interested in paying for TV content, the analyst believes. Furthermore, Netflix will face more competition from other Internet TV services overseas than in the U.S., according to Sena, who cut his 2015 consolidated operating income estimate for the company by 26% to $381M from $517M previously. In addition to cutting his rating, Sena lowered his price target on the shares to $380 from $450. PRICE ACTION: In early trading, Netflix sank $16, or 3.7%, to $422.
10:35 EDTGPROGoPro falls, levels to watch
Subscribe for More Information
10:28 EDTNFLXOptions with increasing implied volatility
Options with increasing implied volatility: PVA NFLX BMRN DNOW MYL TEVA PEP GE
10:02 EDTNFLXOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:37 EDTNFLX, TWTRActive equity options trading on open
Subscribe for More Information
08:37 EDTTWTRTwitter verified offering becoming more likely, says Pacific Crest
Subscribe for More Information
08:23 EDTSNYPCSK9 data continues to impress, says Leerink
Subscribe for More Information
07:52 EDTNFLXNetflix downgraded at Evercore ISI
As previously reported, Evercore ISI downgraded Netflix to Sell from Hold. The firm downgraded shares and reduced its price target to $380 from $450 due to increasing competition among existing and emerging distributors combined with content providers who are becoming increasingly leveraged to new channels through OTT offerings of their own. Evercore ISI believes intensifying competition will necessitate increased investment with uncertain returns and lowered estimates.
07:16 EDTSNYRegeneron Sanofi dupilumab drug can generate $6B+ in revenue, says Bernstein
Bernstein believes that dupilumab, a drug made by Regeneron and Sanofi, has shown strong efficacy in patients with severe atopic dermatitis. The firm notes that the drug is currently in pivotal trials involving patients with severe levels of other common diseases. The firm thinks the drug can generate $1.5B of revenue by 2018 and $3.8B by 2020. Bernstein keeps a $500 price target and Outperform rating on Regeneron.
06:40 EDTSNYPCSK9 studies show potential improvement in heart health, WSJ says
Subscribe for More Information
06:16 EDTNFLXNetflix downgraded to Sell from Hold at Evercore ISI
06:11 EDTTWTRTwitter blocks Meerkat access to social network data, Buzzfeed says
Subscribe for More Information
March 15, 2015
13:04 EDTSNYSanofi, Regeneron announce publication of results of ODYSSEY long term trial
Sanofi (SNY) and Regeneron Pharmaceuticals (REGN) today announced that 18-month results of a Phase 3 trial of Praluent, alirocumab, an investigational therapy, involving 2,341 high risk patients with hypercholesterolemia were published online in The New England Journal of Medicine. In the ODYSSEY LONG TERM trial, Praluent 150 mg every two weeks reduced low-density lipoprotein cholesterol by an additional 62% at week 24 when compared to placebo, the primary efficacy endpoint of the study, with consistent LDL-C lowering maintained over 78 weeks."These results demonstrated the durable efficacy for Praluent when added to maximally-tolerated statin therapy and further reinforce its generally consistent safety profile," said Jennifer Robinson, M.D., M.P.H., Director of the Prevention Intervention Center, Professor, Departments of Epidemiology & Medicine, College of Public Health at the University of Iowa. "Additionally, the post hoc analysis of major cardiovascular events represents an important finding for Praluent -- we look forward to results from the ongoing ODYSSEY OUTCOMES trial, which is prospectively evaluating the potential of Praluent to reduce cardiovascular events."
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use